Acta NaturaeActa NaturaeActa Naturae2075-8251Acta Naturae Ltd1077710.32607/20758251-2010-2-1-102-107ArticlesСтатьиResearch ArticleChanges in the Proteasome Pool during Malignant Transformation of Mouse Liver CellsChanges in the Proteasome Pool during Malignant Transformation of Mouse Liver CellsAstakhovaT MDeloneG VLyupinaYu VAbramovaE BUryvaevaI VSharovaN Pnpsharova@bk.ruKoltsov Institute for Developmental Biology, Russian Academy of Sciences1503201021VOL 2, NO1 (2010)ТОМ 2, №1 (2010)10210717012020Copyright ©; 2010, Astakhova T.M., Delone G.V., Lyupina Y.V., Abramova E.B., Uryvaeva I.V., Sharova N.P.Copyright ©; 2010, Astakhova T.M., Delone G.V., Lyupina Y.V., Abramova E.B., Uryvaeva I.V., Sharova N.P.2010Astakhova T.M., Delone G.V., Lyupina Y.V., Abramova E.B., Uryvaeva I.V., Sharova N.P.Astakhova T.M., Delone G.V., Lyupina Y.V., Abramova E.B., Uryvaeva I.V., Sharova N.P.https://creativecommons.org/licenses/by/4.0https://actanaturae.ru/2075-8251/article/view/10777

Multiple forms of proteasomes regulate cellular processes by destroying proteins or forming the peptides involved in those processes. Various pathologies, including carcinogenesis, are related to changes in functioning the proteasome forms. In this study, we looked at the changes in the pool of liver proteasomes during nodular regenerative hyperplasia and formation of adenoma and hepatocellular carcinoma in mice treated with Dipin, followed by partial liver resection. The relative content of various proteasome forms was determined using Western blot analysis. The chymotrypsin-like activity of proteasomes was assessed from the hydrolysis of the commercial Suc-LLVY-AMC substrate. It was found that changes in the proteasome pool appeared already during the formation of diffuse nodules, the changes being the increased expression of the X(β5) constitutive subunit and the LMP7(β5i) and LMP2(β1i) immune subunits, accompanied by the increase of the total proteasome pool and the decrease in the chymotrypsin-like activity. These changes were more pronounced in hepatocellular carcinoma. The content of the total proteasome pool and the LMP2(β1i) immune subunit and the chymotrypsin-like activity in adenoma were intermediate compared to those in the samples of liver with diffuse nodules and carcinoma. In addition, the level of the Rpt6 subunit present in the 19S proteasome activator was increased in carcinoma. Our results indicate that nodular regenerative hyperplasia and adenomatosis may be stages preceding carcinogenesis. We also conclude that there is a need to find signalling pathways that change the expression of various proteasome subunits during carcinogenesis. The l9S proteasome activator, which is overexpressed in malignant tumours, can be a promising target for the development of new anticancer drugs.

immunoproteasomesl9S proteasome activatorchymotrypsin-like activity of proteasomesWestern blot analysisnodular regenerative hyperplasia of the liveradenomahepatocellular carcinomamouse liver. ABBREVIATIONS nNOS - neuronal nitric oxide synthasedipin - l4-Bis-[NN’-di(Ethylene)-phosphamide]piperazineSuc-LLVY-AMC - N-succinyl-leu-leu-val-tyr7-amido-4-methyl coumarinMGl32 - Z-leucyl-leucyl-leucinalmAb -monoclonal antibodypAb - polyclonal antibodyRock K.L., Goldberg A.L. // Annu. Rev. Immunol 1999. V. 17. P. 739-779.Sharova N. P. // Ontogenesis. 2006. V. 37. P. 171-178 (in Russian).Sharova N., Zakharova L. // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery. 2008. V. 2. P. 152-161.Tanaka K. // Proc. Jpn. Acad., Ser. B. 2009. V. 85. P. 12-36.Caudill C.M., Jayarapu K., Elenich L., et al. // J. Immunol 2006. V. 176. P. 4075-4082.Singh S., Awasthi N., Egwuagu C., Wagner B.J. // Arch. Biochem. Biophys. 2002. V. 405. P. 147-153.Kotamraju S., Matalon S., Matsunaga T., et al. // Free Rad. Biol. Med. 2006. V. 40. P. 1034-1044.Grune T., Reinheckel T., Davies K.J.A. // J. Biol. Chem. 1996. V. 271. P. 15504-15509.Voigt A., Salzmann U., Seifert U., et al. // Biochem. Biophys. Res. Commun 2007. V. 355. P. 549-554.Yuksek K., Chen W.L., Chien D., Ou J.H. // J. Virol 2009. V. 83. P. 612-621.Meidenbauer N., Zippelius A., Pittet M.J., et al. // Cancer Res. 2004. V. 64. P. 6319-6326.Gobbi G., Mirandola P., Micheloni C., et al. // Int. J. Oncol 2004. V. 25. P. 1625-1629.Chen L., Madura K. // Cancer Res. 2005. V. 65. P. 5599-5606.Barnes C.J., Li F., Talukder A.H., Kumar R. // Clin. Cancer Res. 2005. V. 11. P. 2868-2874.Mehling M., Simon P., Mittelbronn M., et al. // Acta Neuropathol 2007. V. 114. P. 111-119.Deng S., Zhou H., Xiong R., et al. // Breast Cancer Res. Treat. 2007. V. 104. P. 21-30.Uryvaeva I.V. // Monogr. Dev. Biol. 1992. V. 23. P. 230-236.Uryvaeva I.V. // Bull Exper. Biol Med. 1997. V. 124. P. 364-368 (in Russian).Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. // J. Biol. Chem. 1951. V. 193. P. 265-275.Ben-Shahar S., Komlosh A., Nadav E., et al. // J. Biol. Chem. 1999. V. 274. P. 21963-21972.Becker F.F. // Cancer Res. 1982. V. 42. P. 3918-3923.Groettrup M., Standera S., Stohwasser R., Kloetzel P.-M. // Proc. Natl. Acad. Sci. USA. 1997. V. 94. P. 8970-8975.Griffin T.A., Nandi D., Cruz M., et al. // J. Exp. Med. 1998. V. 187. P. 97-104.Buldyaeva T.V., Bazarnova (Astakhova) T.M., Kuzmina S.N., Zbarski I.B. // Exper. Oncol 1984. V. 6. P. 35-38 (in Russian).Bazarnova (Astakhova) T.M., Buldyaeva T.V., Filatova L.S., Akopov S.B., and Zbarsky I.B. // Cell Res. 1998. V. 8. P. 195-207.Juckett M.B., Weber M., Balla J. // Free Rad. Biol. Med. 1996. V. 20. P. 63-73.Gorbunov N.V., Yalowich J.C., Gaddam A., et al. // J. Biol. Chem. 1997. V. 272. P. 12328-12341.Kondakova I.V., Zagrebelnaya G.V. // Biomed. Chem. 2004. V. 50. P. 571-581 (in Russian).Krasnov P., Michurina T., Packer M.A., et al. // Mol. Med. 2008. V. 14. P. 141-149.Field-Smith A., Morgan G.J., Davies F.E. // Ther. Clin. Risk. Manag. 2006. V. 2. P. 271-279.Naujokat C., Fuchs D., Berges C. // Biochim. Biophys. Acta. 2007. V. 1773. P. 1389-1397.